Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.
Back
Pembrolizumab Plus Radiation and Surgery Improves DFS in Soft Tissue Sarcoma
Yvonne Mowery, MD, PhD, discusses the phase 2 SU2C-SARC032 trial (NCT03092323) investigating the addition of pembrolizumab (Keytruda) to preoperative radiotherapy and surgery in patients with soft tissue sarcoma.
Pembrolizumab Plus Radiation and Surgery Improves DFS in Soft Tissue Sarcoma
Episodes
All
All
The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.
Dr Mowery discusses the SU2C-SARC032 trial of pembrolizumab plus preoperative radiotherapy and surgery in patients with soft-tissue sarcoma.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
3
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5